Drugs / Mencevax™ ACWY
Mencevax™ ACWY
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00126984 | Jul 2005 → Feb 2008 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00196976 | Mar 2005 → Mar 2006 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00196963 | Mar → Jul 2005 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00127855 | Mar 2003 → Feb 2004 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00453986 | Apr → Nov 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00291343 | Feb 2006 → Mar 2007 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00136604 | Jan → Apr 2006 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00228917 | Jun 2005 → Jan 2006 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00290329 | Jan → Oct 2006 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00227422 | Jun → Nov 2005 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT00390143 Comparator | Feb 2007 → May 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00356369 Comparator | Dec 2006 → Sep 2007 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01154088 Comparator | Aug → Dec 2010 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00464815 Comparator | May 2007 → Apr 2008 | meningococcal infection | GlaxoSmithKline | Completed | Mixed |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-06-22 | GlaxoSmithKline | Regulatory update on divestment of Nimenrix and Mencevax gsk.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mencevax ACWY | “The purpose of this study is to evaluate that the vaccine produced with the new process and administered as a single dose is at least as good as the existing Mencevax™ ACWY...” NCT00227422 ↗15“subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0.” NCT00453986 ↗ “vs Mencevax ACWY (Subcutaneously)” NCT00356369 ↗ “active control (Mencevax™ ACWY)” NCT00196963 ↗ |
| Known as | Men-PS | “1025 adolescents were randomized (3:1) to receive one dose of ACWY-TT or tetravalent ACWY polysaccharide vaccine (Mencevax™, Men-PS).” PMID 21343698 ↗ Feb 2011 |
| Known as | Mencevax | “1025 adolescents were randomized (3:1) to receive one dose of ACWY-TT or tetravalent ACWY polysaccharide vaccine (Mencevax™, Men-PS).” PMID 21343698 ↗ Feb 2011 |
| Known as | Purified Meningococcal Polysaccharide of Serogroup ACWY Vaccine | “GlaxoSmithKline Philippines has submitted a registration file for its Purified Meningococcal Polysaccharide of Serogroup ACWY Vaccine (Mencevax ACWY).” NCT00290329 ↗ |
| Modality | Vaccine | “Meningitec™ or Mencevax™ ACWY vaccine will serve as active control.” NCT00126984 ↗ |
| Route | Subcutaneous | “One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination...” NCT00126984 ↗ |